Novavax Inc. /zigman2/quotes/202614340/composite NVAX +1.14% said Friday that Israel has granted an import and use permit for the company's COVID vaccine for use in people aged 12 and older. The vaccine is protein based, using a more traditional technology than the mRNA used in the vaccines developed by Pfizer Inc. /zigman2/quotes/202877789/composite PFE -0.16% and German partner BioNTech SE /zigman2/quotes/214419716/composite BNTX +1.31% and Moderna Inc. /zigman2/quotes/205619834/composite MRNA -1.27% . The vaccine has now received authorization for use in adults aged 18 and older from more than 40 markets, including the U.S. It has also won authorization from the World Health Organization. Separately, the company said it has also won emergency use authorization in Taiwan for adolescents aged 12 through 17. Novavax shares were down 1.7% premarket and have fallen 77% in the year to date, while the S&P 500 /zigman2/quotes/210599714/realtime SPX -0.16% has fallen 18%.